An interventional study of Mechanical Prophylaxis and aPDT with Erythrosine in Dental Plaque, sponsored by University of Nove de Julho. Not yet recruiting. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled clinical trial aims to evaluate the immediate antimicrobial effectiveness and clinical feasibility of blue LED-mediated antimicrobial photodynamic therapy (aPDT) using plaque-disclosing agents as photosensitizers in children aged 3 to 7 years classified as having high caries risk. Seventy-five participants will be randomly allocated to three parallel groups: mechanical prophylaxis, aPDT with erythrosine, or aPDT with GC TriPlaque ID Gel. Dental biofilm will be assessed at baseline (T0) and immediately after the intervention (T1) during the same clinical session. The primary outcome will be the change in viable microbial load expressed as log10 CFU/mL. Secondary and exploratory microbiological assessments will include quantitative polymerase chain reaction (qPCR) and 16S rRNA gene sequencing, respectively. Clinical feasibility will be assessed based on intervention time and children's behavioral acceptance.
This randomized controlled clinical trial will evaluate the immediate antimicrobial effectiveness and clinical feasibility of blue LED-mediated antimicrobial photodynamic therapy (aPDT) using plaque-disclosing agents as photosensitizers in children aged 3 to 7 years classified as having high caries risk. A total of 75 children will be randomly allocated into three parallel groups (n=25 per group): (1) mechanical prophylaxis (control group), (2) aPDT using erythrosine as a photosensitizer, and (3) aPDT using GC TriPlaque ID Gel as a photosensitizer. Dental biofilm samples will be collected at baseline (T0) and immediately after the intervention (T1), during the same clinical session. At each assessment time point, three separate dental biofilm samples will be collected using sterile No. 0 curettes from the cervical third of the buccal surface of the study tooth, a primary maxillary molar. To ensure comparability between assessments, pre- and post-intervention samples will be collected, in all groups, from the same anatomical site. One sample will be designated for culture-based colony-forming unit (CFU) analysis, one for quantitative polymerase chain reaction (qPCR), and one for 16S rRNA gene sequencing. The primary outcome will be the change in viable microbial load, expressed as log10 CFU/mL, from baseline to immediately after the intervention. qPCR will be used as a secondary microbiological outcome to quantify selected microorganisms associated with caries, whereas 16S rRNA gene sequencing will be used as an exploratory outcome to assess microbial community composition and diversity. Clinical feasibility will be assessed based on intervention time and children's behavioral acceptance. No longitudinal follow-up is planned.
354 studies on the registry are indexed under Dental Plaque; 61 are open to participants now.
This study's planned enrollment of 75 is above the median of 56 across 318 interventional studies indexed under Dental Plaque.
Browse Dental Plaque studies →University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive mechanical prophylaxis using a Robinson brush at low speed with water, without the use of photosensitizers or blue LED irradiation.
Procedure: Mechanical Prophylaxis
Participants will receive antimicrobial photodynamic therapy (aPDT) using erythrosine as a photosensitizer followed by blue LED irradiation. Mechanical prophylaxis will be performed after post-intervention sample collection.
Procedure: aPDT with Erythrosine
Participants will receive antimicrobial photodynamic therapy (aPDT) using GC TriPlaque ID Gel as a photosensitizer followed by blue LED irradiation. Mechanical prophylaxis will be performed after post-intervention sample collection.
Procedure: aPDT with GC TriPlaque ID Gel
Mechanical removal of dental plaque using a Robinson brush at low speed with water, without the use of photosensitizers or light activation.
Also known as: Dental cleaning
Application of erythrosine as a photosensitizer followed by blue LED irradiation using a dental curing light to promote antimicrobial photodynamic therapy.
Also known as: Antimicrobial photodynamic therapy with erythrosine
Application of GC TriPlaque ID Gel as a photosensitizer followed by blue LED irradiation using a dental curing light to promote antimicrobial photodynamic therapy.
Also known as: Antimicrobial photodynamic therapy with GC TriPlaque ID Gel
Change in viable microbial load of dental biofilm (log10 CFU/mL)
Dental biofilm samples will be collected from the cervical third of the buccal surface of a primary maxillary molar at baseline (T0) and immediately after the intervention (T1), during the same clinical session. The primary outcome will be the change in viable microbial load, expressed as log10 CFU/mL, determined by culture-based colony-forming unit analysis.
Time frame: Baseline and Periprocedural
Clinical feasibility of the protocol
Assessment of the total duration of the clinical procedure, measured in minutes using a stopwatch from the beginning to the end of the intervention, to evaluate the feasibility of the protocol in pediatric patients.
Time frame: Baseline and Periprocedural
Child behavioral acceptance
Behavioral response of children during the clinical procedure assessed using the Frankl Behavior Rating Scale (scores 1 to 4), evaluating cooperation and acceptance of the treatment.
Time frame: Baseline and Periprocedural
Change in selected caries-associated microorganisms quantified by qPCR
Dental biofilm samples collected at baseline (T0) and immediately after the intervention (T1) will be analyzed by quantitative polymerase chain reaction (qPCR) for selected microorganisms associated with caries. Quantified microbial values derived from standard curves will be used to compare changes between pre- and post-intervention assessments and among study groups.
Time frame: Baseline and Periprocedural
Change in dental biofilm microbial community composition and diversity assessed by 16S rRNA gene sequencing
Dental biofilm samples collected at baseline (T0) and immediately after the intervention (T1) will undergo 16S rRNA gene sequencing. Microbial community composition will be characterized by taxonomic profiling, relative abundance of identified bacterial taxa, alpha diversity, and beta diversity. Changes between pre- and post-intervention assessments and differences among study groups will be explored.
Time frame: Baseline and Periprocedural
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
Of 135 non-industry interventional studies with no phase under Dental Plaque, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 5 months is below that.
Counting every sponsor, half of 180 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2026 → Dec 2026, primary completion Jun 2026 → May 2027 and completion Aug 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.